In an exciting medical breakthrough, the U.S. Food and Drug Administration (FDA) has approved two sickle cell treatments, including the first to use gene-editing tool CRISPR. Hundreds of thousands of people around the world — mostly people of colour — live with this painful condition that shortens a person's lifespan. Farah Nasser explains how the new therapy works, and what else it could be used for.